DUPHALAC (lactulose), hypoammonaemic osmotic laxative
Reason for request
Moderate clinical benefit for hepatic encephalopathy and constipation
DUPHALAC has been granted a marketing authorisation for hepatic encephalopathy and for the symptomatic treatment of constipation.
In cases of constipation, it should only be envisaged after lifestyle and dietary measures have failed and in combination with such measures.
In cases of hepatic encephalopathy, it is recommended in cases of minimal or subclinical encephalopathy as a first-line symptomatic treatment in the acute phase, supplementing triggering factor management, and for preventing recurrences, with a non-optimal level of evidence.